Drug Search Results
More Filters [+]

Rociletinib

Alternative Names: rociletinib
Latest Update: 2024-03-05
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Clovis Oncology
Company Location: BOULDER CO 80301
Company CEO: Patrick J. Mahaffy
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rociletinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NSCLC

P2

Terminated

Non-Small-Cell Lung Cancer

2019-07-30

NCT02705339

P2

Withdrawn

Non-Small-Cell Lung Cancer

2019-11-01

CO-1686-008

P2

Terminated

Non-Small-Cell Lung Cancer

2018-07-03

TIGER-3

P3

Terminated

Non-Small-Cell Lung Cancer

2018-03-29

Recent News Events